















home - ferring pharmaceuticals usa



































































 































menu










 link for twitter profile for ferring usa
link for facebook profile for ferring usa
link for youtube page for ferring usa
link for linkedin profile for ferring usa
link for instagram profile for ferring usa




contact us
media
collaborate


















menumenubuilding families &improving lives

 focus areas

 patient assistance programs

 access to investigational drugs

 grants & funding

reproductive medicine
gastroenterology & microbiome
orthopaedics
urology and uro-oncology
patient assistance programs
hub resources
access to investigational drugs
investigator-initiated trials
medical education grants
sponsorships & charitable donations

science &innovation

 our scientific approach

 research & development

 
 
believing in the power of research
research and development
product pipeline
clinical trials
drug discovery & early clinical development

products

 reproductive medicine & maternal health

 gastroenterology & microbiome

 orthopaedics

 urology & uro-oncology

 endocrinology

menopur® (menotropins for injection)
endometrin® (progesterone)
novarel® (chorionic gonadotropin for injection, usp)
cervidil® (dinoprostone, 10 mg)
rebyota™ (fecal microbiota, live – jslm) suspension for rectal use
clenpiq® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution
euflexxa® (1% sodium hyaluronate)
adstiladrin® (nadofaragene firadenovec-vncg)
firmagon® (degarelix for injection)
zomacton® (somatropin) for injection

join us

 ferring + you

 your life at ferring

 your application

 
why ferring?
our mission & purpose
diversity, equity & inclusion
awards & recognitions
your wellbeing & benefits
your career development
summer intern program
search opportunities
application process
join our talent community
eeo policy
privacy notice

about ferringusa

 about ferring usa 

 sustainability

 approach

 
about us
mission
leadership
history
culture
giving back
compliance
ethics
locations
commitment to sustainability
reducing inequalities
protecting women and families
our conduct
mission statement
ferring philosophy
leadership principles
diversity & inclusion






search icon button
search for:




 
 
 







home





















first real-world outcomes data for adstiladrin® (nadofaragene firadenovec-vncg) to be presented at asco gu 2025
read more
greenferring highlights commitment to c. diff infection community on the second rebyota® launch anniversary
read more
ferring advances three studies in adstiladrin® (nadofaragene firadenovec-vncg) clinical trial program
read more
ferring announces u.s. fda advisory committee meeting for si-6603 (condoliase)
read more
greenhistoric trenton bridge and nj capitol dome go green for c. diff infection awareness month
read more
greenferring presents new data analyses for rebyota® at acg 2024
read more
blueferring’s dedication to advancing fertility care highlighted at asrm 2024
read more
greenferring presents real-world data analyses at idweek 2024
read more



previous


next




 
 











life-changing therapies to help people build families and live better lives



at ferring, we are committed to helping people build families and live better lives. in the united states, ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.



 









people & families
 


 






learn more


 

 















science & innovation
 


 






learn more


 






believing in the power of research



each of us at ferring contribute to providing innovative solutions to help people live better lives. we devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.



 

 












join us



at ferring pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. with over 6,000 employees in more than 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.



 









join usclick the edit button to change this text.

 






learn more


 

 















about ferring
 


 






learn more


 






helping people live better lives



ferring pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within gastroenterology, including microbiome therapeutics, and orthopaedics.



 

 







 




news

 










press release 2025



											first real-world outcomes data for adstiladrin® (nadofaragene firadenovec-vncg) to be presented at 2025 asco genitourinary cancers symposium										



											february 12, 2025										
										-
										
											by
											robthingee										



											independent experience at three mayo clinic sites and real-world outcomes data with adstiladrin in patients with high-risk bacillus calmette-guérin (bcg)-unresponsive non-muscle invasive bladder ca...										



read more




													0
												












press release 2025



											ferring highlights commitment to c. diff infection community on the second anniversary of the launch of rebyota® (fecal microbiota, live – jslm)										



											january 27, 2025										
										-
										
											by
											robthingee										



											fda approved to prevent recurrent c. difficile infection (rcdi), rebyota is widely available with a strong drug supply and dedicated manufacturing facility since launch, ferring created rebyota @ h...										



read more




													0
												












press release 2024



											ferring advances three studies in adstiladrin® (nadofaragene firadenovec-vncg) clinical trial program										



											december 3, 2024										
										-
										
											by
											robthingee										



											ferring activates first sites in a three-arm study of adstiladrin as a monotherapy or in combination with chemotherapy or an immune checkpoint inhibitor in high-risk bacillus calmette-guérin (bcg)-...										



read more




													0
												










 
 



















 back

 at ferring, we are committed to helping people build families and live better lives. in the united states, ferring is a leader in reproductive medicine and maternal health, uro-oncology and in specialty areas within orthopaedics and gastroenterology including microbiome therapeutics.

 
 link for twitter profile for ferring usa
link for facebook profile for ferring usa
link for youtube page for ferring usa
link for linkedin profile for ferring usa
link for instagram profile for ferring usa


 

legallegal disclaimer
privacy
sharps disposal
locations
 

 contact us

global locator
media inquiries
report a side effect
 

 ferring worldwide

 


 








                                this website provides general information about ferring in the united states. for information about the global company or its products in another specific country, please select your area of interest under "ferring worldwide" above.

© 2024 ferring. ferring and the ferring pharmaceuticals logo and, unless otherwise specified, all product names and service names are trademarks owned by, or licensed to, the ferring group of companies. all other trademarks are the property of their respective owner(s). us-corp-2300030                                        
                        





















 




















































